Eli Lilly and Company (LLY)vsOption Care Health Inc (OPCH)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
OPCH
Option Care Health Inc
$23.48
-0.63%
HEALTHCARE · Cap: $3.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1299% more annual revenue ($79.67B vs $5.69B). LLY leads profitability with a 33.5% profit margin vs 3.7%. LLY appears more attractively valued with a PEG of 1.11. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
OPCH
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-0.1%
Fair Value
$34.63
Current Price
$23.48
$11.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
1.9% revenue growth
3.7% margin — thin
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : OPCH
The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : OPCH
The primary concerns for OPCH are Revenue Growth, Profit Margin, Debt/Equity. Thin 3.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while OPCH is a value play — different risk/reward profiles.
OPCH carries more volatility with a beta of 0.61 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 60/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Option Care Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?